您的位置>>首页 > 师资队伍
师资队伍
陈妍
基本情况
姓名: 陈妍
性别:
职称: 教授
是否博导:
最高学历: 研究生
最高学位: 博士
电话:
Email:
详细情况
所在学科专业: 微生物
所研究方向: 主要研究方向为生物大分子传递系统的研究,包括蛋白多肽类大分子药物传递载体研究、基因治疗载体研究、疫苗佐剂研究。
讲授课程: 本科生课程:药剂学-2和药事管理
研究生课程:现代疫苗进展
教育经历: 2005年沈阳药科大学获药物制剂学专业博士学位。
工作经历: 2005年始就职于吉林大学生命科学学院、艾滋病国家工程实验室。
科研项目:
[1] 项目负责人,吉林省省级产业创新专项资金计划,2018C004,艾滋病国家工程实验室新型疫苗佐剂创新技术平台建设,经费50万元。项目执行期限:2018.01-2019.12。
[2] 项目负责人,国家自然基金面上项目,81572561,双靶向多功能纳米传递载体在卵巢癌多靶点联合治疗中的作用及机制研究,经费78万元。项目执行期限:2016.01-2019.12。
[3] 项目负责人,吉林省产业技术创新战略联盟项目,20140309007YY,新型疫苗佐剂平台,经费80万元。项目执行期限:2014.01-2016.12。
[4] 项目第一参与人,国家自然科学基金青年基金,81201764,双靶向多功能纳米基因传递载体在鼻咽癌生物治疗中的作用及机制研究,经费23万元。项目执行期限:2013.01-2015.12。
[5] 项目负责人,十二五卫生部国家重大专项子课题,2012ZX10001-009-08,重组流感疫苗质量标准研究及多亚型基因疫苗安全性评价,经费150万元。项目执行期限:2011.01-2015.12。
[6] 项目负责人,中央高校基本科研业务费项目——科学前沿与交叉学科创新项目,201103184,鼻咽癌靶向性壳聚糖/PEI/DNA复合物基因控释载体的研究,经费5万元。项目执行期限:2011.04-2013.04。
[7] 项目负责人,国家自然科学基金青年基金,30901863,一种缺血性心脏病基因治疗靶向传递载体的研究,经费22万元。项目执行期限:2010.01-2012.12。
[8] 项目负责人,十一五卫生部国家重大专项子课题,2008X10001-012-03,脂质体包埋HIV-1MPER段抗原对其诱导抗体的结合活性与中和活性的影响,经费100万元。项目执行期限:2008.10-2011.12。
学术论文:
[1] Feng Li,Yan Chen, Shubo Liu, Jian Qi, Weiying Wang, Chenhua Wang, Ruiyue Zhong, Zhijun Chen, Xiaoming Li, Yuanzhou Guan, Wei Kong, Yong Zhang*. Size-controlled fabrication of zein nano/microparticles by modified anti-solvent precipitation with/without sodium caseinate. Int J Nanomed, 2017,12:8197-8209. (IF: 4.3000)
[2] Feng J,Chen Y, Li F, Cui L, Shi N, Kong W, Zhang Y*. Synthesis, Characterization and In Vitro Evaluation of a Novel Glycol Chitosan-EDTA Conjugate to Inhibit Aminopeptidase-Mediated Degradation of Thymopoietin Oligopeptides. Molecules. 2017, 26;22(8):2-11. ( IF:2.861)
[3] Yong Zhang* , Lili Cui, Feng Li, Nianqiu Shi, Chunlei Li, Xianghui Yu, Yan Chen*, Wei Kong. Design,fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int J Pharm.2016,513:191-210.( IF: 3.994)
[4] Sun Y, Wang M, Sun B, Li F, Liu S, Zhang Y*, Zhou Y, Chen Y*, Kong W. An Investigation into the Gastrointestinal Stability of Exenatide in the Presence of Pure Enzymes, Everted Intestinal Rings and Intestinal Homogenates. Biol Pharm Bull. 2016;39(1):42-8. (IF: 1.849) 4区
[5] Zhang Yong*, Cui Lili, Che Xiaoxia, Zhang Heng, Shi Nianqiu, Li Chunlei, Chen Yan*, Kong Wei. Zein-based films and their usage for controlled delivery: Origin, classes and current landscape. J Control Release. 2015, 206:206-219 (IF: 7.261)
[6] Zhang Y*, Feng J,Cui L, Zhang Y, Li W, Li C, Shi N, Chen Y*,Kong W. Investigation into Efficiency of a Novel Glycol Chitosan-Bestatin Conjugate to Protect Thymopoietin Oligopeptides from Enzymatic Degradation. J Pharm Sci. 2016 ,105(2):828-837. (IF: 3.007)
[7] Mengshu Wang, Yong Zhang, Bingxue Sun, Yanan Sun, Xin Gong, Yongge Wu, Xizhen Zhang, Wei Kong*,Yan Chen*. Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine. Biol. Pharm. Bull. 2014;37(5):740-7. (IF: 1.849)
[8] Wang Mengshu, Zhang Yong, Feng Jiao, Gu Tiejun, Dong Qingguang, Yang Xu, Sun Yanan, Wu Yongge, Chen Yan*, Kong Wei*. Preparation, characterization and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int J Nanomed, 2013, 8:1141-1154. (IF: 3.463)
[9] Qing-Guang Dong, Yong Zhang, Meng-Shu Wan, Jiao Feng, Hai-Hong Zhang, Yong-Ge Wu, Tie-Jun Gu, Xiang-Hui Yu, Chun-Lai Jiang, Yan Chen*,Wei Li, Wei Kong*. Improvement of enzymatic stability and intestinal permeability of deuterohemin-peptide conjugates by specific multi-site N-methylation. Amino Acids ,2012, 43:2431-2441. (IF: 3.914)
[10] Wang MS, Sun BX, Feng J, Zhang HH, Liu B, Li C, Chen Y*, Zhang Y*, Kong W. Investigation of transport mechanism of exendin-4 across MDCK cell monolayers. Biol. Pharm. Bull. 2012, 35(5) 745-752. (IF: 1.849)
[11] Bin Liu, Qingguang Dong, Mengshu Wang, Lin Shi, Yongge Wu, Xianghui Yu, Yanyu Shi, Yaming Shan, Chunlai Jiang, Xizhen Zhang, Tiejun Gu, Yan Chen*, Wei Kong*. Preparation, Characterization, and Pharmacodynamics of Exenatide-Loaded Poly(DL-lactic-co-glycolic acid) Microspheres. Chem. Pharm. Bull., 2010, 58(11): 1474-1479. (IF: 1.564)
[12] Bin Liu, Qingguang Dong, Lin Shi, Mengshu Wang, Chun Li, Yongge Wu, Xianghui Yu, Yaming Shan, Yan Chen*, Wei Kong*, Jiacong Shen. Development and Validation of a Reverse-phase High Performance Liquid Chromatography Method for Determination of Exenatide in Poly(lactic-co-glycolic acid) Microspheres. Chemical Research in Chinese Universities, 2010, 26(1), 33-37. (IF: 0.735)
[13] Y. L. HAO, Y. J. DENG, Y. CHEN*, et al. Synthesis hexadecyl 3-{4-[2-hydroxy-3 (isopropylamino) propoxy]phenyl}propionate as potential ligand for liposome targeting to ischemic myocardium. Chinese Chemical Letters, 2005, 16(8): 1004-1006. (IF: 1.587)
[14] Zhang Y, Cui L, Chen Y, Zhang H, Zhong J, Sun Y, Shi N, Li C, Kong W. Zein-based Nanofibres for Drug Delivery: Classes and Current Applications. Curr Pharm Des. 2015;21(22):3199-207. (IF: 3.288)
[15] Ye Duan, Tiejun Gu, Xizhen Zhang, Chunlai Jiang, Ruosen Yuan, Zhuang Li, Dandan Wang, Xiaoxu Chen, Chunlai Wu, Yan Chen, Yongge Wu, Wei Kong. Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57. Molecular Immunology. 2014, 59(2): 136-141. (IF: 2.645)
[16]Bo Sun, XiangHui Yu, Wei Kong, Shiyang Sun, Ping Yang, Changlin Zhu, Haihong Zhang, Yongge Wu, Yan Chen, Yuhua Shi, Xizhen Zhang, Chunlai Jiang, Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor, Appl Microbiol Biotechnol, (2013) 97:1063-1070 (IF 3.425 )
[17] Zhang Haihong, Wang Yuqian, Liu Chenlu, Zhang Lixing, Xia Qiu, Zhang Yong, Wu Jiaxin, Jiang Chunlai, Chen Yan, Wu Yongge, Zha Xiao, Yu Xianghui*, Kong Wei*.DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012,61:1857-1867. (IF 3.701)
[18] Ye Duan, Tiejun Gu, Chunlai Jiang, Ruosen Yuan, Huafei Zhang, Hongjia Hou, Xianghui Yu, Yan Chen, Yong Zhang, Yongge Wu, Wei Kong, A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency. Molecular Immunology, 51 (2012) 188–196.(IF:2.916)
[19] Tie-jun Gu, Wei Wei, Ye Duan1,Chun-lai Jiang, Yan Chen, Xiang-hui Yu, Jia-xin Wu, Yong-ge Wu* and Wei Kong*. Identification of Binding Epitope for Anti-Rabies Virus GlycoproteinSingle-Chain Fv Fragment FV57. Protein & Peptide Letters, 2011, 18, 1099-1106. (IF 1.942)
[20] Q. You, C. Jiang, Y. Wu, X. Yu, Y. Chen, X. Zhang, W. Wei, Y. Wang, Z. Tang, D. Jiang,Y. Wu, C. Wang, X. Meng, X. Zhao, W. Kong, Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis (SJI-11-224), Scandinavian Journal of Immunology 75, 77-84. (IF 1.935)

着作教材: 邓英杰 主编,《脂质体技术》,人民卫生出版社,2007年1月,参编其中3章,约13万字。
获奖情况: [1] 心血管疾病主动靶向治疗等新技术的基础与应用研究. 辽宁省科学技术进步奖二等奖,2014.09,辽宁省科学技术奖励委员会, 3/9. (获奖编号:2014J-2-46)
[2] HIV感染机制和人体对HIV免疫保护机制的研究,吉林省自然科学奖一等奖,2013.09,吉林省科学技术奖励委员会,5/10
[3] 腺病毒载体的预存免疫及解决策略的相关研究,吉林省自然科学学术成果奖二等奖,2013.09,吉林省自然科学学术成果奖评审委员会,9/9
[4] 宫颈癌HPV感染、病毒基因突变以及DNA疫苗的非病毒载体构建,中国抗癌协会科技奖三等奖,2009.05,中国抗癌协会,7
[5] 沈阳市科学技术进步一等奖( 2005-1-10-7)
社会兼职: 吉林省药学会生物制品专业委员会

版权所有:吉林大学生命科学学院 2018 © 电话:+(86)-431-81969061

地址:吉林省长春市前进大街2699号生命科学楼 邮编:130012   Power by leeyc